한글목차

임상시험 매칭 소프트웨어 세계 시장 규모는 2024년에 1억 5,776만 달러에 달했고, 예측 기간 동안 8.55%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다.

이 시장은 임상시험 프로토콜의 복잡성, 정밀의료의 부상, 환자 모집 과정의 효율화라는 절박한 요구를 배경으로 큰 견인차 역할을 하고 있습니다.

임상시험이 세계화되고, 전자의무기록(EHR), 유전체 시퀀싱, 병력 등 다양한 소스로부터 방대한 데이터 세트를 수집하는 데이터 집약형으로 변화함에 따라, 환자와 적절한 시험을 효율적으로 매칭할 수 있는 지능형 소프트웨어 플랫폼에 대한 신뢰가 높아지고 있습니다. 이러한 플랫폼은 임상 연구와 관련된 물류 및 재정적 문제를 극복하는 데 있어 중요한 운영 도구가 되고 있습니다.

환자 모집은 여전히 임상시험의 가장 큰 장애물 중 하나이며, 종종 지연과 예산 초과를 유발하는 원인이 되기도 합니다. 적격 환자를 수작업으로 식별하는 것은 일반적으로 시간이 오래 걸리고 실수가 발생하기 쉽습니다. 임상시험 매칭 소프트웨어는 인공지능(AI) 및 머신러닝(ML)과 같은 첨단 기술을 활용하여 이 문제를 해결합니다. 이러한 시스템은 구조화된 환자 데이터와 비구조화된 환자 데이터를 모두 분석하여 복잡한 포함 및 제외 기준을 충족하는 후보자를 정확하게 식별함으로써 모집 일정을 단축하고 임상시험 성공률을 높입니다.

주요 시장 성장 촉진요인

개인 맞춤형 의료에 대한 수요 증가

주요 시장 이슈

데이터 프라이버시 및 보안

주요 시장 동향

인공지능과 머신러닝의 통합

목차

제1장 개요

• 시장의 정의
• 시장 범위
  • 대상 시장
  • 조사 대상년
  • 주요 시장 세분화

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 임상시험 매칭 소프트웨어 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 전개 모드별(웹 및 클라우드 기반, 온프레미스)
  • 최종 용도별(제약 기업 및 바이오테크놀러지 기업, CRO, 의료기기 기업)
  • 지역별
  • 기업별(2024년)
• 제품 시장 맵

제6장 북미의 임상시험 매칭 소프트웨어 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 임상시험 매칭 소프트웨어 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인

제8장 아시아태평양의 임상시험 매칭 소프트웨어 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 일본
  • 인도
  • 호주
  • 한국

제9장 남미의 임상시험 매칭 소프트웨어 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 임상시험 매칭 소프트웨어 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 최근 동향
• 인수합병(M&A)
• 제품 출시

제13장 Porter의 Five Forces 분석

• 업계내 경쟁
• 신규 참여 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제14장 경쟁 구도

• IBM Clinical Development
• Antidote Technologies Inc
• Ofni Systems Inc
• SSS International Clinical Research GmbH
• CLARIO
• Advarra Inc
• ArisGlobal LLC
• Bsi Business Systems Integration AG
• Teckro Ltd
• Clinical Trials Mobile Application

제15장 전략적 제안

제16장 리서치사에 대해 & 면책사항

영문목차

The Global Clinical Trials Matching Software Market was valued at USD 157.76 million in 2024 and is expected to register robust growth during the forecast period, with a projected compound annual growth rate (CAGR) of 8.55% through 2030. The market is gaining significant traction, driven by the increasing complexity of clinical trial protocols, the rise of precision medicine, and the pressing need to enhance the efficiency of patient recruitment processes.

As clinical trials become more globalized and data-intensive-incorporating vast datasets from diverse sources such as electronic health records (EHRs), genomic sequences, and medical histories-there is a growing reliance on intelligent software platforms that can efficiently match patients to appropriate studies. These platforms have become a critical operational tool in overcoming the logistical and financial challenges associated with clinical research.

Patient recruitment remains one of the most significant hurdles in clinical trials, often causing delays and budget overruns. Manual identification of eligible participants is typically time-consuming and error-prone. Clinical trials matching software addresses this issue by leveraging advanced technologies such as artificial intelligence (AI) and machine learning (ML). These systems analyze both structured and unstructured patient data to accurately identify candidates that meet complex inclusion and exclusion criteria, thereby accelerating recruitment timelines and increasing trial success rates.

Key Market Drivers

Rising Demand for Personalized Medicine

Personalized medicine is transforming the healthcare landscape by enabling tailored treatment strategies based on an individual's genetic profile, lifestyle, and specific health conditions. This approach is not only enhancing patient outcomes but also reshaping the pharmaceutical research model. As the demand for personalized therapies grows, it is fueling an increase in clinical trial activity and driving the need for advanced patient-matching technologies.

Also referred to as precision medicine, this approach moves away from the traditional "one-size-fits-all" treatment model and focuses on individualized care informed by genetic, molecular, and environmental factors. It has shown particular success in oncology, where therapies are developed to target specific genetic mutations, resulting in more effective and less toxic treatments.

The implementation of personalized medicine requires in-depth genetic profiling and biomarker identification, generating vast amounts of complex data that must be analyzed and validated through clinical trials. Clinical trials matching software is pivotal in managing this data and accelerating the recruitment of appropriate trial participants, ensuring the timely execution of research and improving the likelihood of clinical success.

Key Market Challenges

Data Privacy and Security

One of the primary challenges confronting the clinical trials matching software market is the management of data privacy and security. These platforms handle highly sensitive information, including patients' medical records, genetic data, and other personal health details. Ensuring compliance with stringent data protection regulations-such as the Health Insurance Portability and Accountability Act (HIPAA) in the United States and the General Data Protection Regulation (GDPR) in the European Union-is both complex and resource-intensive.

Failure to adhere to these regulations can result in legal repercussions, reputational damage, and loss of stakeholder trust. As a result, software developers must prioritize robust security frameworks and ensure their platforms are fully compliant with global data protection standards.

Key Market Trends

Integration of Artificial Intelligence and Machine Learning

The adoption of artificial intelligence (AI) and machine learning (ML) technologies is emerging as a major trend in the clinical trials matching software market. These technologies are enhancing the ability of software platforms to process large volumes of data, identify eligible trial candidates, and predict patient responses to investigational therapies.

ML-powered tools not only improve recruitment efficiency but also support smarter trial design and real-time monitoring, which ultimately accelerates drug development timelines. As AI capabilities continue to evolve, their integration into clinical trial workflows is expected to redefine how trials are conducted, from protocol design to patient engagement and outcome analysis.

Key Market Players

• IBM Clinical Development
• Antidote Technologies Inc
• Ofni Systems Inc
• SSS International Clinical Research GmbH
• CLARIO
• Advarra Inc
• ArisGlobal LLC
• Bsi Business Systems Integration AG
• Teckro Ltd
• Clinical Trials Mobile Application

Report Scope:

In this report, the Global Clinical Trials Matching Software Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Clinical Trials Matching Software Market, By Deployment Mode:

• Web & Cloud-based
• On-premises

Clinical Trials Matching Software Market, By End-use:

• Pharmaceutical & Biotechnology Companies
• CROs
• Medical Device Firms

Clinical Trials Matching Software Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Clinical Trials Matching Software Market.

Available Customizations:

Global Clinical Trials Matching Software market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Service Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Clinical Trials Matching Software Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Deployment Mode (Web & Cloud-based, On-premises)
  • 5.2.2. By End-use (Pharmaceutical & Biotechnology Companies, CROs, Medical Device Firms)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Product Market Map

6. North America Clinical Trials Matching Software Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Deployment Mode
  • 6.2.2. By End-use
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Clinical Trials Matching Software Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Deployment Mode
      • 6.3.1.2.2. By End-use
  • 6.3.2. Canada Clinical Trials Matching Software Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Deployment Mode
      • 6.3.2.2.2. By End-use
  • 6.3.3. Mexico Clinical Trials Matching Software Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Deployment Mode
      • 6.3.3.2.2. By End-use

7. Europe Clinical Trials Matching Software Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Deployment Mode
  • 7.2.2. By End-use
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Clinical Trials Matching Software Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Deployment Mode
      • 7.3.1.2.2. By End-use
  • 7.3.2. United Kingdom Clinical Trials Matching Software Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Deployment Mode
      • 7.3.2.2.2. By End-use
  • 7.3.3. France Clinical Trials Matching Software Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Deployment Mode
      • 7.3.3.2.2. By End-use
  • 7.3.4. Italy Clinical Trials Matching Software Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Deployment Mode
      • 7.3.4.2.2. By End-use
  • 7.3.5. Spain Clinical Trials Matching Software Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Deployment Mode
      • 7.3.5.2.2. By End-use

8. Asia-Pacific Clinical Trials Matching Software Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Deployment Mode
  • 8.2.2. By End-use
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Clinical Trials Matching Software Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Deployment Mode
      • 8.3.1.2.2. By End-use
  • 8.3.2. Japan Clinical Trials Matching Software Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Deployment Mode
      • 8.3.2.2.2. By End-use
  • 8.3.3. India Clinical Trials Matching Software Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Deployment Mode
      • 8.3.3.2.2. By End-use
  • 8.3.4. Australia Clinical Trials Matching Software Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Deployment Mode
      • 8.3.4.2.2. By End-use
  • 8.3.5. South Korea Clinical Trials Matching Software Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Deployment Mode
      • 8.3.5.2.2. By End-use

9. South America Clinical Trials Matching Software Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Deployment Mode
  • 9.2.2. By End-use
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Clinical Trials Matching Software Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Deployment Mode
      • 9.3.1.2.2. By End-use
  • 9.3.2. Argentina Clinical Trials Matching Software Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Deployment Mode
      • 9.3.2.2.2. By End-use
  • 9.3.3. Colombia Clinical Trials Matching Software Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Deployment Mode
      • 9.3.3.2.2. By End-use

10. Middle East and Africa Clinical Trials Matching Software Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Deployment Mode
  • 10.2.2. By End-use
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Clinical Trials Matching Software Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Deployment Mode
      • 10.3.1.2.2. By End-use
  • 10.3.2. Saudi Arabia Clinical Trials Matching Software Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Deployment Mode
      • 10.3.2.2.2. By End-use
  • 10.3.3. UAE Clinical Trials Matching Software Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Deployment Mode
      • 10.3.3.2.2. By End-use
  • 10.3.4. Kuwait Clinical Trials Matching Software Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Deployment Mode
      • 10.3.4.2.2. By End-use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. IBM Clinical Development
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. Antidote Technologies Inc
• 14.3. Ofni Systems Inc
• 14.4. SSS International Clinical Research GmbH
• 14.5. CLARIO
• 14.6. Advarra Inc
• 14.7. ArisGlobal LLC
• 14.8. Bsi Business Systems Integration AG
• 14.9. Teckro Ltd
• 14.10. Clinical Trials Mobile Application

15. Strategic Recommendations

16. About Us & Disclaimer